AU781276B2 - The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions - Google Patents

The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions Download PDF

Info

Publication number
AU781276B2
AU781276B2 AU76529/01A AU7652901A AU781276B2 AU 781276 B2 AU781276 B2 AU 781276B2 AU 76529/01 A AU76529/01 A AU 76529/01A AU 7652901 A AU7652901 A AU 7652901A AU 781276 B2 AU781276 B2 AU 781276B2
Authority
AU
Australia
Prior art keywords
atrial
mammal
aerp
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76529/01A
Other languages
English (en)
Other versions
AU7652901A (en
Inventor
Mireille Marguerite Jeanne Bonhomme
Antoine Michel Alain Bril
Bernard Emile Joseph Gout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire GlaxoSmithKline SAS
Glaxo Group Ltd
Original Assignee
Laboratoire GlaxoSmithKline SAS
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Laboratoire GlaxoSmithKline SAS, Glaxo Group Ltd filed Critical Laboratoire GlaxoSmithKline SAS
Publication of AU7652901A publication Critical patent/AU7652901A/en
Priority to AU29161/02A priority Critical patent/AU782863C/en
Publication of AU781276B2 publication Critical patent/AU781276B2/en
Application granted granted Critical
Assigned to LABORATOIRE GLAXOSMITHKLINE S.A.S., GLAXO GROUP LIMITED reassignment LABORATOIRE GLAXOSMITHKLINE S.A.S. Amend patent request/document other than specification (104) Assignors: GLAXO GROUP LIMITED, LABORATOIRE GLAXOSMITHKLINE S.A.S., SMITHKLINE BEECHAM CORPORATION
Priority to AU2005203196A priority patent/AU2005203196B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU76529/01A 2000-08-07 2001-08-07 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions Ceased AU781276B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29161/02A AU782863C (en) 2000-08-07 2002-03-27 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU2005203196A AU2005203196B9 (en) 2000-08-07 2005-07-21 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0019410 2000-08-07
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019523 2000-08-08
GB0019524 2000-08-08
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0118919 2001-08-02
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
GB0119022 2001-08-03
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU29161/02A Division AU782863C (en) 2000-08-07 2002-03-27 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU29162/02A Division AU782870C (en) 2000-08-07 2002-03-27 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Publications (2)

Publication Number Publication Date
AU7652901A AU7652901A (en) 2002-02-18
AU781276B2 true AU781276B2 (en) 2005-05-12

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76529/01A Ceased AU781276B2 (en) 2000-08-07 2001-08-07 The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Country Status (16)

Country Link
US (3) US20050032866A1 (enExample)
EP (1) EP1311295A2 (enExample)
JP (2) JP2004505930A (enExample)
KR (1) KR20030027010A (enExample)
CN (1) CN100413539C (enExample)
AU (1) AU781276B2 (enExample)
BR (1) BR0113073A (enExample)
CA (1) CA2418904A1 (enExample)
CZ (1) CZ2003366A3 (enExample)
HU (1) HUP0303075A3 (enExample)
IL (1) IL154279A0 (enExample)
MX (1) MXPA03001210A (enExample)
NO (1) NO20030588L (enExample)
NZ (1) NZ524108A (enExample)
PL (1) PL365048A1 (enExample)
WO (1) WO2002011766A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007857A (es) * 2002-02-14 2004-10-15 Glaxo Group Ltd Composicion farmaceutica que comprende n-((1-butil -4-piperidinil) metil)-3, 4-dihidro-2h -(1, 3)oxazino (3, 2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco.
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
EP3176164B1 (en) 2014-07-30 2019-08-21 Aetas Pharma Co. Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
CA2118812C (en) * 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
MX9301837A (es) * 1992-03-31 1994-02-28 Glaxo Group Ltd Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende.
SK116394A3 (en) * 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
ATE171446T1 (de) * 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
ES2151743T3 (es) * 1996-08-16 2001-01-01 Smithkline Beecham Plc Procedimiento para la preparacion de n-((1-n-butil-4-piperidinil)metil)-3,4-dihidro-2h-(1,3)-oxazino(3,2-a)indol-10-carboxamida y las sales y productos intermedios en el procedimiento.
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
EP0884319A2 (en) * 1992-03-12 1998-12-16 Smithkline Beecham Plc [1,3]oxazino[3,2-A]indole derivative
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists

Also Published As

Publication number Publication date
CN100413539C (zh) 2008-08-27
BR0113073A (pt) 2004-06-22
HUP0303075A3 (en) 2007-03-28
JP2004505930A (ja) 2004-02-26
EP1311295A2 (en) 2003-05-21
MXPA03001210A (es) 2004-08-12
PL365048A1 (en) 2004-12-27
US20050032866A1 (en) 2005-02-10
WO2002011766A2 (en) 2002-02-14
WO2002011766A3 (en) 2002-08-01
IL154279A0 (en) 2003-09-17
NO20030588D0 (no) 2003-02-06
NO20030588L (no) 2003-04-03
US20070015769A1 (en) 2007-01-18
CZ2003366A3 (en) 2004-04-14
US20080125422A1 (en) 2008-05-29
CN1468112A (zh) 2004-01-14
AU7652901A (en) 2002-02-18
HUP0303075A2 (hu) 2003-12-29
NZ524108A (en) 2004-11-26
CA2418904A1 (en) 2002-02-14
KR20030027010A (ko) 2003-04-03
JP2007145869A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
US20220133778A1 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2870123C (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
HUP0001527A2 (hu) Laktózmentes, nem higroszkópos és vízmentes dekarboetoxiloratadin-tartalmú gyógyászati készítmények
NZ547152A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
CA2609627C (en) Pharmaceutical formulations useful for inhibiting acid secretion
US20080125422A1 (en) Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
MX2007000632A (es) Composicion antihistaminica.
AU782870B2 (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU782863B2 (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU2005203196B9 (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
JP2008500365A (ja) 酸分泌を阻害するために有用な薬学的製剤ならびにその製造方法および使用方法
CA2593854A1 (en) Organic compounds
Woroń Drug selection in the treatment of breakthrough pain: how the pharmacokinetic profile of drugsis to be translated into clinical practice
TW200425914A (en) Pharmaceutical tablet composition comprising n-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide (sb 207266) or a salt thereof
AU2005331781C1 (en) Pharmaceutical formulations useful for inhibiting acid secretion
AU2011265561B2 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN101297807A (zh) 5-ht4受体拮抗剂在预防或治疗某些心血管疾病中的应用